

REVIEW ARTICLE

Dan L. Longo, M.D., *Editor*

Myeloproliferative Neoplasms

Jerry L. Spivak, M.D.

From the Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore. Address reprint requests to Dr. Spivak at the Hematology Division, Johns Hopkins University School of Medicine, Traylor 924, 720 Rutland Ave., Baltimore, MD 21205, or at jlsipivak@jhmi.edu.

N Engl J Med 2017;376:2168-81.

DOI: 10.1056/NEJMra1406186

Copyright © 2017 Massachusetts Medical Society.

THE MYELOPROLIFERATIVE NEOPLASMS — POLYCYTHEMIA VERA, ESSENTIAL thrombocytosis, and primary myelofibrosis — are unique hematopoietic stem-cell disorders that share mutations that constitutively activate the physiologic signal-transduction pathways responsible for hematopoiesis (Table 1). Consequently, these disorders engage in phenotypic mimicry among themselves, as well as with myeloid neoplasms and even benign hematopoietic disorders. In contrast to the myeloid neoplasms, the myeloproliferative neoplasms have a natural history, with supportive care alone, that is usually measured in decades rather than years.¹ However, a facade of benign myeloproliferation masks a clone of transformed hematopoietic stem cells capable of expansion and transformation to an aggressive form of bone marrow failure or acute leukemia, albeit at varying frequencies in each of these disorders. In addition to phenotypic mimicry, each type of myeloproliferative neoplasm is capable of evolving into another type, making diagnosis, risk assessment, and therapeutic choices difficult. Furthermore, despite more than a century of scrutiny, the pathogenesis of myeloproliferative neoplasms has been enigmatic, and therapy largely supportive. Recently, however, driver mutations have been identified in more than 90% of patients with myeloproliferative neoplasms, providing substantial insight into their pathogenesis. The current challenge is to integrate this new knowledge with the accumulated decades of clinical knowledge to improve diagnosis, risk assessment, and therapy.

MUTATIONAL LANDSCAPE

HOST GENETIC VARIATION

Host genetic variation, including sex and age, has an essential role in the mutational landscape of myeloproliferative neoplasms.² Genomewide association studies have identified single-nucleotide variants that increase the probability that such neoplasms will develop. For example, in one study, a single-nucleotide variant haplotype, designated 46/1 (GGCC) and located in *cis* on the Janus kinase 2 (*JAK2*) allele, was associated with an increase by a factor of 3 in the risk of a *JAK2*-activating mutation³; in other studies, other single-nucleotide variants were associated with mutations in the genes encoding calreticulin (*CALR*) and the thrombopoietin receptor (*MPL*),⁴ or the individual myeloproliferative neoplasms.^{4,5} These genetic predispositions may explain the co-occurrence of stem-cell clones harboring *JAK2*, *MPL*, or *CALR* mutations^{6,7} in the same person.

It is important to note that a single-nucleotide variant in *TERT*, which is linked to activated myeloid hematopoiesis, is associated with all three myeloproliferative neoplasms⁸ but most significantly with their familial forms,⁹ and this variant, in combination with 46/1 and other single-nucleotide variants, has an additive effect on susceptibility to myeloproliferative neoplasms.^{4,5} The *TERT* variant also confers a predisposition to the co-occurrence of solid tumors in patients with myeloproliferative neoplasms.¹⁰

HEREDITARY AND FAMILIAL MYELOPROLIFERATIVE DISORDERS

In addition to these common but weakly penetrant single-nucleotide variants that increase disease susceptibility, rare but highly penetrant germline mutations in the *JAK2* JH1 and JH2 domains¹¹ (Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org) and the *MPL* transmembrane domain¹² (Fig. S3 in the Supplementary Appendix) cause hereditary thrombocytosis, mimicking sporadic, clonal essential thrombocytosis, including myelofibrotic transformation.¹³ Conversely, germline single-nucleotide variants in the *MPL* extracellular domain, which occur in 7% of African-American populations¹⁴ and 6% of Arabic populations,¹⁵ have a benign thrombocytosis phenotype.

In adults, myeloproliferative neoplasms due to somatic *JAK2*, *MPL*, or *CALR* mutations are usually sporadic. However, 7% of cases involve a familial predisposition (a feature unique to these disorders), with first-degree relatives of an affected patient at increased risk, by a factor of 5 to 7, for the same myeloproliferative neoplasm (in some families) or for different myeloproliferative neoplasms (in other families), involving *JAK2*, *MPL*, and *CALR* mutations or no identifiable mutation.^{16,17} Predisposing genetic risk factors include female sex and the *TERT* single-nucleotide variant. Penetrance is incomplete, and generational skipping occurs.

GENOTYPE AND PHENOTYPE RELATIONSHIPS

Table 2, and Table S1 in the Supplementary Appendix, list the most common gene mutations associated with clinical phenotypes of myeloproliferative neoplasms. Myeloproliferative neoplasms have a low mutation frequency (0.2 per megabase), as do the myeloid neoplasms, and likewise, the median number of mutations (6.5 in essential thrombocytosis and polycythemia vera and 13.0 in myelofibrosis) is similar.¹⁸ Mutation number is a function of host age, not disease duration or a particular driver mutation. Pathogenic mutations have been identified in more than 90% of patients with myeloproliferative neoplasms; 50 to 60% of patients have only a driver mutation: *JAK2* V617F, *CALR*, *MPL*, or in rare cases, *LNK*⁷; the remainder have additional mutations, most often affecting genes coding for signal transduction or for epigenetic regulatory, tumor-suppressor, or splicing proteins. Such grouping belies the fact that mutated genes in one category fre-

quently influence function in another category¹⁹ and rarely operate alone; remarkably, as few as two mutations can shorten the life span.^{7,20}

In “triple-negative” patients (i.e., those who have a myeloproliferative neoplasm phenotype [Table 2] but do not have canonical *JAK2*, *MPL*, or *CALR* driver mutations), novel somatic or germline *JAK2* or *MPL* mutations have been identified by means of deep sequencing. Other patients have been found to have a clonal disorder without a defined driver mutation, and in some patients, hematopoiesis is polyclonal, a feature that is consistent with a hereditary disorder.^{21,22}

AGE, SEX, AND PHENOTYPE

In adults, sporadic acquisition of a myeloproliferative neoplasm driver mutation by a hematopoietic stem cell does not guarantee its clonal expansion at the expense of unaffected stem cells⁸; clonal expansion appears to be dictated in part by the patient’s sex and age.^{23,24} For example, *JAK2* V617F acquisition can occur at any age, but myeloproliferative neoplasms are uncommon before the age of 50 years, and two of the three types — polycythemia vera and essential thrombocytosis — occur mainly in women. After the age of 60 years, the incidence of myeloid and myeloproliferative neoplasms increases exponentially²⁵ in association with an increased incidence of *DNMT3A*, *TET2*, *ASXL1*, *JAK2* V617F, and *TP53* mutations.²⁶ In this age group, myeloproliferative neoplasms are more common in men than in women and are associated with primary myelofibrosis and acute leukemia. The order of mutation acquisition does not affect the clinical phenotype.²⁷

EPIGENETIC AND CYTOGENETIC ABNORMALITIES

Aberrant DNA methylation is a feature of the myeloproliferative neoplasms that is independent of driver mutations and is associated with disease transformation²⁸; the mechanisms are undefined. Most patients do not have *DNMT3a* or *TET2* mutations, which regulate DNA methylation and, by extension, the size of the hematopoietic stem-cell pool. Patients do, however, have age-associated changes in stem-cell DNA methylation that mimic cancer-associated DNA methylation abnormalities²⁹ and promote stem-cell monoclonality.³⁰

Altered DNA methylation, associated with

both age and mutations, also causes DNA breakage,³¹ leading to gene deletions (del5q, del7q, and del17p) and duplications (8q and MYC). These are as important prognostically with respect to leukemic transformation as are acquired point mutations.^{32,33} Telomere shortening occurs in myeloproliferative neoplasms,³⁴ but whether it is associated with aneuploidy is unknown.

GENE EXPRESSION

Gene-expression profiling integrates the consequences of genetic abnormalities for cellular

processes. Neutrophil gene expression in patients with myeloproliferative neoplasms differs from expression in persons without such neoplasms but does not differ among the three diseases³⁵; notably, there is activation of genes involved in inflammatory signaling pathways, including interleukin-6, interleukin-8, interleukin-10, granulocyte–macrophage colony-stimulating factor, and transforming growth factor (TGF) β .³⁶ By contrast, hematopoietic stem-cell gene expression in patients with the three types of myeloproliferative neoplasms not only differs from expression in persons without such neoplasms

Table 1. Types of Myeloproliferative Neoplasms and Associated Driver Mutations.

Types of Myeloproliferative Neoplasms

Polycythemia vera, the most common myeloproliferative neoplasm, is a panmyelopathy and the ultimate phenotypic consequence of *JAK2* gain-of-function gene mutations and, in rare cases, *CALR* or *LNK* mutations. Unlike the two other types of myeloproliferative neoplasms, polycythemia vera is characterized by erythrocytosis, with a progressive increase over time in erythropoiesis, granulopoiesis, and thrombopoiesis. The most common complications are arterial and venous thrombosis due to red-cell-mass–induced hyperviscosity; transient ischemic attacks, ocular migraine, or erythromelalgia due to activated platelets; aquagenic pruritus due to activated basophils; acquired von Willebrand's disease and pseudohyperkalemia due to extreme thrombocytosis; splenomegaly due to migration of the involved hematopoietic stem cells from the marrow (extramedullary hematopoiesis); and in some patients, transformation to bone marrow failure, myelofibrosis, and acute leukemia.

Essential thrombocytosis, the most indolent myeloproliferative neoplasm, is characterized by thrombocytosis alone and is caused by *JAK2* V617F, *CALR*, or *MPL* mutations and infrequently by germline single-nucleotide variants. Complications include transient ischemic attacks, ocular migraine, erythromelalgia, acquired von Willebrand's disease, and pseudohyperkalemia due to extreme thrombocytosis, and less commonly, arterial or venous thrombosis and transformation to bone marrow failure, myelofibrosis, and acute leukemia. Essential thrombocytosis is a diagnosis of exclusion because the thrombopoietin receptor, *MPL*, is the only hematopoietic growth factor receptor expressed by hematopoietic stem cells, and isolated thrombocytosis may be the first manifestation of polycythemia vera or primary myelofibrosis.

Primary myelofibrosis, the least common and most aggressive myeloproliferative neoplasm, is caused by *JAK2* V617F, *CALR*, or *MPL* mutations and is manifested as new bone marrow fibrosis, splenomegaly due to extramedullary hematopoiesis, an increase in circulating CD34+ cells, anemia, variable changes in the platelet and leukocyte counts, and constitutional symptoms due to inflammatory cytokine production. The disease has a progressive course characterized by bone marrow failure; organ failure due to extramedullary hematopoiesis, including pulmonary hypertension; and transformation to acute leukemia.

Driver mutations

JAK2 is the most common myeloproliferative neoplasm driver gene. A member of the Janus kinase family, *JAK2* serves as the cognate tyrosine kinase for the erythropoietin and thrombopoietin receptors and can also be used by the granulocyte colony-stimulating factor receptor, all of which lack an intrinsic kinase domain. *JAK2* has a dual kinase structure: a canonical tyrosine kinase domain (JH1) paired in tandem with a weakly active pseudokinase domain (JH2), which normally inhibits JH1 kinase activity in the absence of ligand binding (Fig. S1 in the Supplementary Appendix).

Whether the JH1–JH2 interaction occurs in *cis* or *trans* is unresolved, but current data favor an interaction in *trans*, in which the *JAK2* JH2 pseudokinase domain on one receptor monomer inhibits the JH1 kinase domain of the *JAK2* molecule on its partner receptor monomer and vice versa, an inhibition that is abrogated physiologically with receptor–ligand binding as a result of a change in the receptor dimer conformation. The most common myeloproliferative neoplasm mutation, *JAK2* V617F, an exon 14 point mutation in the *JAK2* JH2 pseudokinase domain, impairs its physiologic inhibitory influence on the JH1 kinase domain. How *JAK2* V617F and other JH2 domain mutations alleviate this inhibition is unknown, but the mechanism probably involves changes in the *JAK2* Src homology 2 (SH2)–JH2 linker region, which alter the interface between the JH2 and JH1 domains. In the heterozygous state, *JAK2* V617F–bearing receptors are still responsive to growth factors. Only with *JAK2* V617F homozygosity, usually due to 9p uniparental disomy, do these receptors become autonomous with respect to growth factor. Approximately 3% of patients with polycythemia vera have insertions or deletions in *JAK2* exon 12 at the interface of the *JAK2* SH2 and JH2 domains (Fig. S1 in the Supplementary Appendix), which enable constitutive kinase activation, possibly also by altering the interface between the JH2 and JH1 domains. The *JAK2* exon 12 phenotype is usually more benign than that of *JAK2* V617F, often causing erythrocytosis alone, though a complete polycythemia vera phenotype can develop, as can homozygosity or coexistence with *JAK2* V617F. *JAK2* also serves as an endoplasmic reticulum chaperone for the erythropoietin and thrombopoietin receptors, transporting them to the cell surface, and increases the total number of thrombopoietin receptors by stabilizing the mature form of the receptor, enhancing receptor recycling, and preventing receptor degradation. However, in contrast to its effect on the erythropoietin receptor, *JAK2* V617F appears to increase the quantity of immature *MPL* while increasing *MPL* degradation through ubiquitination and reducing its cell-surface expression. In addition to functioning as a tyrosine kinase and chaperone, mutated *JAK2* is sumoylated, permitting it to shuttle to the nucleus, where it deregulates gene transcription directly through histone phosphorylation and indirectly by phosphorylating and inhibiting PRMT5, a histone arginine methyltransferase.

Table 1. (Continued.)

CALR, the gene that encodes calreticulin, is the second most common myeloproliferative driver gene. Discovered by whole-exome sequencing (Fig. S2 in the Supplementary Appendix), it was an unlikely candidate. CALR is a multifunctional protein involved in glycoprotein folding and calcium homeostasis in the endoplasmic reticulum, as well as in cellular functions such as proliferation, phagocytosis, and apoptosis. CALR mutations consist of a wide variety of deletions or insertions in exon 9, all of which have the same consequence: a 1-bp frame-shift, which removes KDEL, a canonical endoplasmic reticulum retrieval motif, together with a switch from a negatively charged to a positively charged peptide sequence in the CALR C terminal domain. These mutations substantially alter CALR cellular distribution because mutant CALR is able to bind MPL through the receptor's extracellular domain and chaperone it to the plasma membrane. The mutant, positively charged CALR C terminal domain is obligatory for both MPL binding and cellular transformation, but how MPL JAK2 signaling is activated by mutant CALR is unknown. As is the case with JAK2 and MPL mutations, the proportion of immature MPL in the cell is increased. Like receptors containing JAK2 V617F, MPL bound by mutant CALR still requires growth factor stimulation for complete JAK2 activation in the heterozygous state. To date, more than 50 different CALR mutations have been identified and classified according to their effect on DNA sequence: deletions have been designated as type 1 or type 1-like, of which L367fs*46, a 52-bp deletion, is the most common, and insertions as type 2 or type 2-like, of which K385fs*47, a 5-bp insertion, is the most common. Together, these account for 85% of the CALR mutations; type 1 mutations are more common in primary myelofibrosis, whereas type 1 and type 2 occur with similar frequency in essential thrombocytosis. Like JAK2 and MPL mutations, mutated CALR is expressed in hematopoietic stem cells. It is a driver mutation primarily in essential thrombocytosis and primary myelofibrosis; is occasionally homozygous as a result of 19 uniparental disomy, usually with type 2 mutations; is not mutually exclusive of JAK2 V617F; and causes polycythemia vera in rare cases. In some but not all studies, the CALR type 1 mutation appeared to be associated with a survival advantage as compared with JAK2 V617F and MPL mutations, but the three mutations did not differ with respect to leukemic transformation. Among patients with essential thrombocytosis, those with the CALR type 2 mutation were younger and had higher platelet counts than their counterparts with type 1 mutations, and type 1 was more common in men than in women, but there was no difference in survival between the type 1 and 2 mutations or between them and JAK2 V617F or MPL. Myelofibrotic transformation of essential thrombocytosis appeared to be more common with type CALR 1 mutations than with type 2 or JAK2 V617F mutations. Finally, although thrombotic risk appeared to be greater in patients with JAK2 V617F–positive essential thrombocytosis than in their CALR mutation–positive counterparts, this observation must be tempered by the fact that many of the patients with so-called JAK2 V617F–positive essential thrombocytosis had hemoglobin levels that were compatible with polycythemia vera rather than essential thrombocytosis.

MPL, a truncated form of the thrombopoietin receptor gene, is the oncogene of the MPLV retrovirus, which causes murine polycythemia vera. MPL mutations are the least common myeloproliferative neoplasm driver mutations, occurring in primary myelofibrosis and essential thrombocytosis, but overall, compromised MPL function due to incomplete glycosylation and impaired MPL cell-surface expression may have a more important role in the pathophysiology of myeloproliferative neoplasms than any MPL mutation. MPL is a unique type I hematopoietic cytokine receptor because it is the only one expressed in hematopoietic stem cells; it also has a reduplicated extracellular cytokine-binding domain. Somatic MPL mutations occur most often in exon 10 (Fig. S3 in the Supplementary Appendix) and result in a switch from tryptophan to leucine or lysine or, less frequently, to arginine or alanine at amino acid 515 (MPL W515L/K or W515R/A) in the MPL juxtamembrane domain. A less common mutation, S505N, in the MPL transmembrane domain, in which serine is switched to asparagine, can be inherited or acquired and causes essential thrombocytosis. MPL mutations force a change in receptor conformation, activating JAK2 in the absence of thrombopoietin binding. Like JAK2 and CALR mutations, however, MPL mutations require a hematopoietic growth factor, in this case thrombopoietin, for complete kinase activation in the heterozygous state. Myeloproliferative neoplasm driver mutations also occur in the MPL extracellular distal cytokine domain (Fig. S3 in the Supplementary Appendix). For example, MPL S204P/F are acquired mutations causing essential thrombocytosis or primary myelofibrosis, whereas the germline MPL variants, K39N (MPL Baltimore) and P106L, cause a benign form of thrombocytosis in African-American and Arabic populations, respectively, which is most marked in the homozygous state. Somatic MPL mutations and germline single-nucleotide variants are not mutually exclusive of JAK2 V617F, though they are not in the same clone. In patients with essential thrombocytosis, MPL mutations are associated with greater myelofibrotic transformation, but there is no difference in overall or leukemia-free survival between patients with MPL mutations and those with JAK2 V617F, and there appears to be no survival difference between patients with primary myelofibrosis who have MPL mutations and those who have JAK2 V617F mutations. JAK2 V617F impairs MPL maturation, increasing the proportion of immature receptors in the plasma membrane; reduces MPL recycling; and increases its degradation. Impaired MPL cell-surface expression, which is also a feature of CALR and MPL mutations, results in elevated plasma thrombopoietin levels, as a result of reduced clearance of thrombopoietin from the plasma by megakaryocytes and platelets, and may also be involved in the emigration of involved hematopoietic stem cells from their marrow niches (Fig. S4 in the Supplementary Appendix). In this regard, congenital amegakaryocytic thrombocytopenia, an autosomal recessive disorder caused by compound heterozygous or homozygous mutations in the MPL distal cytokine homology domain, which is manifested initially as thrombocytopenia but eventually evolves to aplastic anemia, underscores the central role of MPL in hematopoietic stem-cell physiology.

but also, and more important, differs among the three types of neoplasms, indicating that they are genetically distinct diseases.^{1,23,37-39}

In polycythemia vera, hematopoietic stem-cell gene expression differs between men and women. However, men and women have in common JAK2 V617F–independent expression of 102 genes, which are differentially expressed in patients with

aggressive disease and those with indolent disease. Included are genes involved in stem-cell expansion, myelofibrosis, inflammation, coagulation, and leukemic transformation.²³ A total of 55 of these genes are differentially regulated in chronic and blast-phase chronic myeloid leukemia,²³ suggesting that the two diseases have the same molecular pathways for leukemic transformation.

Table 2. Gene Mutations in the Chronic Phase of Myeloproliferative Neoplasms, According to Phenotype and Driver Mutation.*

Gene Mutation	Polycythemia Vera				Essential Thrombocytosis				Primary Myelofibrosis			
	JAK2 V617F	JAK2 Exon 12	CALR		JAK2 V617F	CALR	MPL	Triple Negative	JAK2 V617F	CALR	MPL	Triple Negative
<i>percent of patients†</i>												
Tyrosine kinases												
JAK2 V617F	92	0	Frequency unknown		55	0	0	Frequency unknown	50	0	0	0
JAK2 exon 12	Frequency unknown	5	NA		0	0	0	0	0	0	0	0
Receptors												
CALR	Frequency unknown	0	Frequency unknown		0	36	0	0	0	30	0	0
MPL	Frequency unknown	0	0		0	0	4	Frequency unknown	Frequency unknown	0	8	0
NTRK1	14	NA	NA		NA	NA	NA	Frequency unknown	10	NA	NA	NA
DNA methylation												
TET2	12	NA	NA		6	NA	NA	NA	12	Frequency unknown	NA	Frequency unknown
DNMT3A	8	NA	NA		9	NA	NA	NA	6	NA	NA	0
IDH1/2	3	NA	NA		0	NA	NA	NA	4	7	0	9
Histone methylation												
ASXL1	7	NA	NA		2	NA	NA	NA	30	32	30	32
EZH2	2	NA	NA		1	NA	NA	NA	7	7	10	5
SUZ12	3	NA	NA		0	NA	NA	NA	3	NA	NA	0
Spliceosome												
U2AF1	0	NA	NA		0	NA	NA	NA	22	2	21	5
SRSF2	0	NA	NA		0	NA	NA	NA	13	3	15	23
SF3B1	10	NA	NA		0	NA	NA	NA	9	2	5	14
ZRSR2	0	NA	NA		0	NA	NA	NA	3	NA	NA	0

Tumor suppressors: TP53	5	NA	NA	NA	NA	5	NA	NA	0
Transcription factors: NF-E2	2	NA	NA	NA	NA	Frequency unknown	Frequency unknown	Frequency unknown	NA
Activated signaling									
NRAS/KRAS	3	NA	NA	NA	NA	0	NA	NA	0
CBL	2	NA	NA	NA	NA	2	NA	NA	Frequency unknown
NF1	3	NA	NA	NA	NA	0	NA	NA	0
SH2B3 (LNK)‡	Frequency unknown	NA	NA	NA	NA	Frequency unknown	Frequency unknown	NA	NA

* “Triple negative” refers to patients with a myeloproliferative neoplasm phenotype who do not have a canonical driver mutation. Some of these patients have germline mutations, suggesting that their disorder is hereditary. NA denotes not available, whereas “frequency unknown” indicates that there are too few reports to allow calculation of a frequency.
‡ The percentages represent the frequency of a particular mutation among patients with the same myeloproliferative neoplasm.
‡‡ Germline LNK single-nucleotide variants appear to influence LNK behavior.

HEMATOPOIETIC STEM-CELL BONE MARROW NICHES

Hematopoietic stem cells reside in two specialized bone marrow niches⁴⁰ (Fig. S4 in the Supplementary Appendix). The proliferative niche is sinusoidal. Here, thrombopoietin promotes DNA synthesis⁴¹ and macrophages nurture developing erythroblasts.⁴² The quiescent niche is endosteal, perfused by arterioles and innervated by sympathetic nerves. Here, stem cells are tethered to osteoblasts through their adhesion and thrombopoietin receptors.⁴¹ Stem-cell quiescence is maintained by CXCL4 and TGF- β 1 secretion from closely apposed megakaryocytes.⁴³

Polycythemia vera stem cells up-regulate inflammatory cytokine genes (as do chronic myeloid leukemia stem cells⁴⁴), including *CCL3*, tumor necrosis factor, *LCN2*, and *LGALS3*,^{23,45} that inhibit normal stem-cell proliferation, promote osteomyelofibrosis, and damage niche sympathetic nerves, enhancing myeloproliferation.⁴⁶ Normal marrow stromal cells can be appropriated by the neoplastic clone to secrete inflammatory cytokines.⁴⁷ These abnormalities are augmented by age-associated microenvironmental changes that promote stem-cell monoclonality and myeloid predominance.³⁰

Myelofibrosis in the myeloproliferative neoplasms is fostered by elevated plasma thrombopoietin levels, possibly as a result of impaired thrombopoietin receptor expression,⁴⁸ that are unrelated to the driver mutation.⁴⁹ Myelofibrosis is a reactive and reversible process that does not impair marrow function.^{20,50} Impaired marrow function is due to the transformed hematopoietic stem cells and occurs in approximately 15 to 20% of patients with polycythemia vera⁵⁰; in some patients, a decline in the phlebotomy rate is an artifact of plasma-volume expansion and is not indicative of a bone marrow “spent phase.”⁵¹

STEM-CELL CLONAL ARCHITECTURE

Driver mutations for myeloproliferative neoplasms are present in the long-term repopulating stem cells that are responsible for maintaining hematopoiesis^{52,53} (Fig. 1) but do not alter the hematopoietic stem-cell hierarchy; instead, they expand the pool of JAK2-sensitive, committed myeloid progenitor cells.⁵⁴ Studies indicate that long-term repopulating stem cells can also differentiate




Figure 1. Hierarchy of Hematopoietic Stem and Progenitor Cells.

Hematopoietic stem cells (HSCs) are organized hierarchically into long-term and short-term HSCs according to their capacity for self-renewal and marrow repopulation. During homeostasis, long-term HSCs maintain the pool of short-term HSCs, which are responsible for daily replenishment of the lymphoid multipotent progenitor-cell (LMPP) and myeloid progenitor-cell (MP) pools. These pools, in turn, give rise to lineage-restricted neutrophil or macrophage, erythroid, megakaryocytic, B-cell, and T-cell progenitors. Lineage-restricted myeloid repopulating (MyRP) HSCs — specifically, megakaryocytic repopulating (MkRP), megakaryocytic-erythroid repopulating (MERP), and common myeloid long-term repopulating (CMRP) stem cells — can arise directly from long-term HSCs. Although *JAK2*, *CALR*, and *MPL* driver mutations arise in long-term HSCs, phenotypic mimicry among the myeloproliferative neoplasms may be due to the differential or changing involvement of specific lineage-restricted HSCs. The thrombopoietin receptor (MPL), in contrast to the granulocyte colony-stimulating factor receptor (G-CSFR) and the erythropoietin receptor (EPO-R), is the only hematopoietic growth factor receptor expressed in long-term HSCs and is essential for HSC osteoblastic niche residence in marrow, maintenance of HSC quiescence, DNA damage repair, and cell-cycle activation.

directly into megakaryocytic, megakaryocytic-erythroid, or myeloid progenitor cells,⁵⁵ which could explain platelet-restricted *JAK2* V617F expression in women with essential thrombocythosis,⁵⁶ the variable phenotypic presentations of polycythemia vera, and the evolution from one myeloproliferative neoplasm to another.

Figure 2 shows the relationship among sex, disease phenotype, disease duration,^{24,57} and the *JAK2* V617F allele burden in neutrophils, which are sensitive to activated *JAK2*, in patients with myeloproliferative neoplasms.⁵⁸ Figure S5 in the Supplementary Appendix shows the effect of these variables on the allele burden in hemo-

poietic stem cells, which are not sensitive to activated *JAK2*.⁵⁴ Clonal dominance occurs when the malignant stem-cell population exceeds the normal one. Clonal dominance drives the disease phenotype, for which the *JAK2* V617F neutrophil allele burden is not a reliable measure,⁵⁷ particularly in polycythemia vera, which is characterized by the slow development of clonal dominance. In primary myelofibrosis, clonal dominance is usually present at diagnosis,⁵⁷ and in essential thrombocythosis, clonal dominance is rare (Fig. S5 in the Supplementary Appendix). It is clear that host genetic variation,² in which sex is an important component,²³ is the major determinant of the myeloproliferative neoplasm phenotype, not specific driver mutations or their allele burdens.

ACUTE LEUKEMIA

Acute myeloid leukemia occurs spontaneously in patients with myeloproliferative neoplasms and has a poor prognosis.⁵⁹ Estimates of the incidence of acute myeloid leukemia range from 1.5% in patients with essential thrombocythosis and 7.0% in patients with polycythemia vera⁶⁰ to 11% in patients with primary myelofibrosis.⁶¹ However, such estimates are confounded by age-related de novo acute leukemia and chemotherapy; chemotherapy increases the incidence to 20%.^{60,62} Acute leukemia in patients with myeloproliferative neoplasms can involve the founding hematopoietic stem-cell clone but more often involves a subclone, as occurs in cases of de novo acute leukemia in patients without such neoplasms.⁵³

The cytogenetic landscape of the myeloproliferative neoplasms is relatively limited and does not differ substantially according to the type of neoplasm.³³ Furthermore, driver mutation status is not associated with the time to leukemic transformation or survival after transformation.³² Disease transformation is associated with older age; acquisition of 9p uniparental disomy; 1q amplification, which involves *MDM4*, the *TP53* inhibitor⁶³; and additional cytogenetic abnormalities and mutations.^{32,33,64}

Acute leukemia originating in a *JAK2* V617F-negative hematopoietic stem cell is a unique feature of *JAK2* V617F-positive myeloproliferative neoplasms (Fig. S6 in the Supplementary Appendix), occurring in approximately 40% of cases,

Figure 2. Sex, Disease Duration, and the JAK2 V617F Neutrophil Allele Burden in Essential Thrombocythosis, Polycythemia Vera, and Primary Myelofibrosis.


The relationship among sex, disease duration, and the neutrophil allele burden is complex in patients with JAK2 V617F–positive essential thrombocythosis, polycythemia vera, or primary myelofibrosis. Essential thrombocythosis is characterized by a neutrophil allele burden of less than 50%, which is constant during the course of the disease, with no difference in allele burden between men and women, even though the disease is more common in women. In polycythemia vera, the neutrophil allele burden is often greater than 50% at diagnosis or subsequently increases over time to more than 50% because of uniparental disomy, but not in all patients, and the burden is usually greater in men than in women. In primary myelofibrosis, the neutrophil allele burden is usually greater than 50% in most patients at diagnosis and is higher in women than in men, even though primary myelofibrosis is more common in men.

most often in chronic-phase polycythemia vera and essential thrombocythosis.⁶⁵

Like acute leukemia in patients with myeloid neoplasms,⁶⁶ acute leukemia in those with myeloproliferative neoplasms can be classified by its mutations as de novo (*DNMT3A*, *NPM1*, and *RUNX1*), secondary to the myeloproliferative neoplasm (*SRSF2*, *EZH2*, and *ASXL1*), or treatment-related (*TP53*, *del7q*, *del7/7q*, and *del17p*), regardless of disease phase or driver mutation. Most worrisome is treatment-related acute leukemia, since it is preventable. Chemotherapy neither averts disease transformation and thrombosis nor prolongs survival, as compared with supportive care.^{60,62,67} Rather, chemotherapy facilitates the selection of drug-resistant stem-cell subclones.⁶⁸

DIAGNOSIS

JAK2, *CALR*, and *MPL* mutations are not mutually exclusive, they are not exclusive to a particular myeloproliferative neoplasm, and their absence does not preclude any of these neoplasms. A positive mutation assay establishes the presence of a hematopoietic stem-cell disorder, not its identity, and surrogate markers such as the serum erythropoietin level⁶⁹ or bone marrow histologic features cannot provide specificity, except that myelodysplasia can be ruled out on the basis of histologic features.^{70,71} All three myeloproliferative neoplasms may be manifested as isolated thrombocythosis, whereas polycythemia vera, the ulti-



mate phenotype of *JAK2* mutations and, in rare cases, *CALR* mutations,⁷² may be characterized by isolated erythrocytosis, leukocytosis, splenomegaly, and even myelofibrosis.⁶⁹

Since each myeloproliferative neoplasm can evolve into the others, diagnosis is a moving target. For example, *JAK2* V617F–positive essential thrombocythosis evolves into polycythemia vera in women more often than in men,²⁴ whereas *JAK2* V617F–positive²⁴ or *CALR* type 1–positive⁷³ essential thrombocythosis in men is more likely to evolve into secondary myelofibrosis; polycythemia vera evolves into myelofibrosis, and primary myelofibrosis evolves into polycythemia vera. Quantification of the driver-mutation allele burden at diagnosis provides a baseline for assessment of clonal evolution (Fig. 2, and Fig. S5 in the Supplementary Appendix).

Erythrocytosis in polycythemia vera, unlike

hypoxic erythrocytosis, usually induces plasma-volume expansion,⁶⁹ masking the true hematocrit (Fig. 3). In many patients, especially women,^{74,75} the hematocrit appears to be normal. Because polycythemia vera is the most common myeloproliferative neoplasm, has the most protean manifestations, and is associated with the highest risk of thrombosis, its identification is paramount when a myeloproliferative neoplasm is a diagnostic consideration. Moreover, because of phenotypic mimicry, polycythemia vera must be ruled out to establish the diagnosis of essential thrombocythosis or primary myelofibrosis, unless an *MPL* mutation is involved.⁷⁴⁻⁷⁶

A hematocrit or erythrocyte count above the normal range for sex, in conjunction with a *JAK2* or *CALR* mutation, establishes the diagnosis of neoplastic erythrocytosis, even in the absence of leukocytosis, thrombocytosis, and splenomegaly;




Figure 3. Effect of Changes in Plasma Volume and Red-Cell Mass on the Venous Hematocrit.

Plasma-volume contraction alone causes an apparent increase in the hematocrit, even though the red-cell mass is unchanged and is indistinguishable on the basis of the hematocrit from an increase in red-cell mass due to hypoxia, since with hypoxia, an increase in erythropoiesis is associated with plasma-volume contraction because maintaining a constant blood volume is the body's default program. In polycythemia vera, however, as the red-cell mass increases, the plasma volume usually increases, masking the erythrocytosis or its extent, a situation further confounded by splenomegaly or pregnancy. Thus, as illustrated in the examples below the graph, without an independent determination of both the red-cell mass and plasma volume, it is not possible, on the basis of the hematocrit, to distinguish plasma-volume contraction from absolute erythrocytosis or even the presence of erythrocytosis, assuming normocytic red cells, if polycythemia vera is a diagnostic consideration. The arrows indicate the plasma volume.

microcytic erythrocytosis, if present, provides a useful clue.⁷⁷ With iron deficiency, the hemoglobin level cannot be substituted for the hematocrit diagnostically and should not be used for therapeutic guidance,⁷⁸ since erythrocytosis, not the hemoglobin level, determines blood viscosity⁷⁹ (Fig. S7 in the Supplementary Appendix). When the hematocrit is apparently normal, especially in patients with splenomegaly, only red-cell mass and plasma-volume measurements can distinguish polycythemia vera from its companion myeloproliferative neoplasms^{69,74}; marrow histologic features have no role in this situation.⁷⁰ Molecular diagnostic assays for these disorders are currently lacking, though data are available for the development of such assays.^{23,37-39}

Finally, a serious consequence of using predetermined hematocrit or hemoglobin levels diagnostically is conflation of polycythemia vera with JAK2 V617F-associated essential thrombocythosis.^{75,78} This inflates the thrombosis rate in JAK2 V617F-positive essential thrombocythosis relative to the rate in essential thrombocythosis associated with a CALR mutation, because CALR mutations rarely cause erythrocytosis.⁷²

THERAPY

Cure is the ultimate objective of cancer therapy, but the hallmark of myeloproliferative neoplasms is their chronicity. On the basis of retrospective data unadjusted for sex, age, driver mutation, or therapy, life expectancy for patients with essential thrombocythosis is normal, whereas the median survival for patients with polycythemia vera and patients with primary myelofibrosis is 27 years and 14 years, respectively.¹ Thus, strategies for accurate risk assessment are essential to maximize therapeutic benefits and avoid unnecessary toxic effects. The therapeutic goals for patients with myeloproliferative neoplasms are symptom alleviation and prevention of thrombosis and transformation to myelofibrosis or acute leukemia.

POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTOSIS

For polycythemia vera and essential thrombocythosis, current therapeutic guidelines stipulate that an age of 65 years or more and a history of thrombosis put patients at high risk for complications, apart from the role of sex, driver or other mutations, allele burdens, and the fact that

thrombosis in polycythemia vera is provoked and related only to the hematocrit.^{80,81} Furthermore, except for hepatic-vein thrombosis in young women,⁸² complications in patients with polycythemia vera do not differ according to age,⁸³ but longevity data notwithstanding, chemotherapy is recommended in both diseases.⁸⁴ Yet prospective, controlled clinical trials^{60,62} and a large retrospective study⁶⁷ have shown that neither chemotherapy nor phosphorus-32 for the treatment of polycythemia vera prevents thrombosis or prolongs survival, and both treatments are associated with an increased risk of leukemic transformation. In patients with essential thrombocythosis, hydroxyurea alleviates transient ischemic attacks but does not prevent either arterial or venous thrombosis and is not otherwise more effective than anagrelide or aspirin,^{85,86} even though it normalizes both the platelet and leukocyte counts. Moreover, attempts to achieve hematologic remission with hydroxyurea have failed to prolong survival.⁸⁷

Dameshek's advice nearly 50 years ago is still apt: "There is a tendency in medical practice — by no means limited to hematologists — to treat almost any condition as vigorously as possible. In hematology, this consists in attempting to change an abnormal *number* — whether this number is the hematocrit, white cell count or platelet count — to get normal values, whether the patient needs it or not!"⁸⁸

Treatment of polycythemia vera relies on phlebotomy. The target hematocrit is below 45% in men and below 42% in women.⁸⁰ The iron deficiency due to phlebotomy can aid in the control of erythrocyte production and rarely needs to be treated unless symptoms in other systems interfere with the quality of life.⁸⁹

Asymptomatic patients with essential thrombocythosis require no therapy⁹⁰; platelet counts exceeding 1 million per cubic millimeter can cause mild acquired von Willebrand's disease as a result of platelet proteolysis of high-molecular-weight von Willebrand multimers, but unprovoked hemorrhage is uncommon.⁹¹ If reduction of the platelet count is necessary, pegylated interferon is preferable to hydroxyurea in patients younger than 65 years of age.⁸⁴ In both polycythemia vera and essential thrombocythosis, aspirin is usually effective for microvascular episodes such as ocular migraine, transient ischemic attacks,⁹² and erythromelalgia due to hyperactive platelets.⁹³ Aspirin has no antithrombotic

benefit in the absence of cardiovascular risk factors.⁹⁴

MYELOFIBROSIS

In patients with secondary myelofibrosis due to either essential thrombocythemia or polycythemia vera, as well as in patients with primary myelofibrosis, longevity is compromised by extramedullary hematopoiesis, marrow failure, and leukemic transformation, regardless of the driver mutation. In patients with primary myelofibrosis, *CALR* type 1 mutations may offer a survival advantage but not freedom from leukemic transformation.⁹⁵ Current prognostic scoring systems for myelofibrosis,^{96,97} which predict median survival and need for therapeutic intervention, are based on the primary myelofibrosis phenotype. These systems are inexact for secondary myelofibrosis⁹⁸ and do not account for the influence of driver or other mutations on survival or leukemic transformation.

With respect to risk stratification, it appears that mutations in *ASXL1*, *EZH2*, *SRSF2*, or *IDH1/2*, with or without a driver mutation, in patients with primary myelofibrosis are independent risk factors for shortened survival²⁰; in patients with secondary myelofibrosis, only *SRSF2* is associated with shortened survival.⁹⁹ Patients without myelofibrosis may also be at risk of leukemic transformation if they acquire a *TP53* mutation, even at a subclonal level.^{7,63}

TARGETED THERAPIES

Chemotherapy has traditionally been used to control intractable pruritus and ocular migraine, as well as extramedullary hematopoiesis associated with myelofibrosis, but it does not avert the need for splenectomy or splenic irradiation. Now, however, there are two effective, nongenotoxic therapies to address these problems: ruxolitinib and interferon.

Ruxolitinib, an inhibitor of JAK1 and JAK2, durably alleviates symptoms, reduces splenomegaly, corrects blood counts,¹⁰⁰ and is effective in patients with hydroxyurea-refractory polycythemia vera.¹⁰¹ Suppression of inflammatory cytokine production and hematopoietic progenitor-cell proliferation appear to be the major effects of ruxolitinib. Hematopoietic stem cells are not appreciably affected, and neither is leukemic transformation. Whether the presence of additional mutations impairs the effectiveness of ruxolitinib is disputed.^{102,103}

Interferon is currently the only agent that specifically targets hematopoietic stem cells in patients with myeloproliferative neoplasms¹⁰⁴; its pegylated derivative alleviates symptoms, reduces splenomegaly, and induces hematologic remission. Durable complete molecular remission has been achieved in 18% of patients with polycythemia vera or essential thrombocythemia,^{105,106} and marrow fibrosis has been ameliorated in some patients with primary myelofibrosis.¹⁰⁷ The influence of nondriver mutations on the effectiveness of interferon is unclear.^{106,108} Neither interferon nor its pegylated derivative is uniformly effective in all patients, and clinically significant side effects, such as immunosuppression, myelotoxicity, and neurotoxicity,¹⁰⁹ limit the use of these drugs in some patients.

BONE MARROW TRANSPLANTATION

Bone marrow transplantation is the only curative therapy for the myeloproliferative neoplasms,¹¹⁰ but several questions remain unanswered. It is unclear whether full allogeneic or haploidentical transplantation should be performed, and there is uncertainty about the conditioning regimen. The most important question, given transplantation-related mortality and the chronicity of myeloproliferative neoplasms, is when to intervene in patients other than those with high-risk myelofibrosis.

FUTURE CONSIDERATIONS

There are two challenges in future therapy for myeloproliferative neoplasms: accurate genetic, as opposed to phenotypic, identification of patients at risk for disease transformation, and eradication of neoplastic hematopoietic stem cells to prevent leukemic transformation. With regard to both challenges, since few oncogenes are recurrently mutated in these disorders and other mechanisms, including cytogenetic and epigenetic abnormalities, are involved in transformation, gene-expression profiling is likely to be the most informative approach for defining risk and identifying molecular pathways for targeted therapy.²³

While new therapies targeting hematopoietic stem cells in myeloproliferative neoplasms are being developed, efforts should be focused on when and how to use the three treatments currently documented as effective — ruxolitinib, pegylated interferon, and bone marrow transplantation — alone or in combination and possibly with epigenetic-modifying drugs to eradicate neoplastic hematopoietic stem cells.

We do not understand why only a minority of patients have a molecular remission with pegylated interferon or what the biologic basis for ruxolitinib failures is. Answers to these questions will come only from prospective, randomized clinical trials combined with molecular analysis to define genomic abnormalities in patients. With respect to new treatment directions, hematopoietic stem cells are most vulnerable in their bone marrow niches (Fig. S4 in the Supple-

mentary Appendix). Consequently, targeting MPL (the thrombopoietin receptor) or its ligand (thrombopoietin) could lead to fruitful, non-genotoxic therapeutic strategies.^{111,112}

Dr. Spivak reports receiving consulting fees from Incyte and holding a patent on a genetic assay to determine prognosis in patients with polycythemia vera (PCT/US2013/069192). No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

I thank Hugh Young Rienhoff, Jr., M.D., for his thoughtful comments.

REFERENCES

1. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood* 2014;124:2507-13.
2. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. *Blood* 2008;111:2785-9.
3. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. *Nat Genet* 2009;41:446-9.
4. Tapper W, Jones AV, Kralovics R, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. *Nat Commun* 2015;6:6691-702.
5. Oddsson A, Kristinsson SY, Helgason H, et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. *Leukemia* 2014;28:1371-4.
6. Beer PA, Jones AV, Bench AJ, et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. *Br J Haematol* 2009;144:904-8.
7. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. *Blood* 2014;123:2220-8.
8. Hinds DA, Barnholt KE, Mesa RA, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. *Blood* 2016;128:1121-8.
9. Jäger R, Harutyunyan AS, Rumi E, et al. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. *Am J Hematol* 2014;89:1107-10.
10. Krahling T, Balassa K, Kiss KP, et al. Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100. *Cancer Epidemiol Biomarkers Prev* 2016;25:98-104.
11. Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. *Blood* 2014;123:1372-83.
12. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. *Blood* 2004;103:4198-200.
13. Teofili L, Giona F, Torti L, et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. *Haematologica* 2009;95:65-70.
14. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. *Proc Natl Acad Sci U S A* 2004;101:11444-7.
15. El-Harith HA, Roesl C, Ballmaier M, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. *Br J Haematol* 2009;144:185-94.
16. Landgren O, Goldin LR, Kristinsson SY, Helgadóttir EA, Samuelsson J, Björkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. *Blood* 2008;112:2199-204.
17. Rumi E, Harutyunyan AS, Pietra D, et al. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. *Blood* 2014;123:2416-9.
18. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *N Engl J Med* 2013;369:2391-405.
19. Khan SN, Jankowska AM, Mahfouz R, et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. *Leukemia* 2013;27:1301-9.
20. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. *Leukemia* 2014;28:1804-10.
21. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. *Blood* 2016;127:325-32.
22. Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. *Blood* 2016;127:333-42.
23. Spivak JL, Considine M, Williams DM, et al. Two clinical phenotypes in polycythemia vera. *N Engl J Med* 2014;371:808-17.
24. Stein BL, Williams DM, Wang NY, et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. *Haematologica* 2010;95:1090-7.
25. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. *Hematol Oncol* 1997;15:173-89.
26. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med* 2014;20:1472-8.
27. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. *N Engl J Med* 2015;372:601-12.
28. Pérez C, Pascual M, Martín-Subero JI, et al. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. *Haematologica* 2013;98:1414-20.
29. Teschendorff AE, Menon U, Gentry-Maharaj A, et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. *Genome Res* 2010;20:440-6.
30. Adams PD, Jasper H, Rudolph KL. Aging-induced stem cell mutations as drivers for disease and cancer. *Cell Stem Cell* 2015;16:601-12.
31. De S, Michor F. DNA secondary structures and epigenetic determinants of cancer genome evolution. *Nat Struct Mol Biol* 2011;18:950-5.
32. Thoenissen NH, Harutyunyan A, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. *Blood* 2010;115:2882-90.
33. Klampfl T, Harutyunyan A, Berg T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during

- disease progression. *Blood* 2011;118:167-76.
34. Ruella M, Salmoiraghi S, Risso A, et al. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. *Exp Hematol* 2013;41:627-34.
 35. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. *Blood* 2014;123(22):e123-e133.
 36. Slezak S, Jin P, Caruccio L, et al. Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. *J Transl Med* 2009;7:39.
 37. Catani L, Zini R, Sollazzo D, et al. Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. *Leukemia* 2009;23:997-1000.
 38. Berkofsky-Fessler W, Buzzai M, Kim MK, et al. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. *Clin Cancer Res* 2010;16:4339-52.
 39. Guglielmelli P, Zini R, Bogani C, et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). *Stem Cells* 2007;25:165-73.
 40. Boulais PE, Frenette PS. Making sense of hematopoietic stem cell niches. *Blood* 2015;125:2621-9.
 41. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. *Cell Stem Cell* 2007;1:685-97.
 42. Chow A, Huggins M, Ahmed J, et al. CD169 macrophages provide a niche promoting erythropoiesis under homeostasis and stress. *Nat Med* 2013;19:429-36.
 43. Zhao M, Perry JM, Marshall H, et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. *Nat Med* 2014;20:1321-6.
 44. Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. *Cell Stem Cell* 2013;13:285-99.
 45. Fleischman AG, Aichberger KJ, Luty SB, et al. TNF α facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. *Blood* 2011;118:6392-8.
 46. Arranz L, Sánchez-Aguilera A, Martín-Pérez D, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. *Nature* 2014;512:78-81.
 47. Kleppe M, Kwak M, Koppikar P, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. *Cancer Discov* 2015;5:316-31.
 48. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. *N Engl J Med* 1998;338:572-80.
 49. Antonioni E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. *Leukemia* 2005;19:1847-9.
 50. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. *Blood* 2008;111:3383-7.
 51. Najean Y, Arrago JP, Rain JD, Dresch C. The 'spent' phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis. *Br J Haematol* 1984;56:163-70.
 52. Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. *J Clin Invest* 2012;122:3888-99.
 53. Gerber JM, Ngwang B, Zhang H, et al. The leukemic stem cell in polycythemia vera and primary myelofibrosis is distinct from the initiating JAK2 V617F-positive hematopoietic stem cell. *Blood* 2011;118:613. abstract.
 54. Anand S, Stedham F, Beer P, et al. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. *Blood* 2011;118:177-81.
 55. Yamamoto R, Morita Y, Ooehara J, et al. Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. *Cell* 2013;154:1112-26.
 56. Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. *Leukemia* 2007;21:2210-2.
 57. Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. *Exp Hematol* 2008;36:1480-6.
 58. Dupont S, Massé A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. *Blood* 2007;110:1013-21.
 59. Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. *Blood* 2013;121:2725-33.
 60. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. *N Engl J Med* 1981;304:441-7.
 61. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. *Acta Haematol* 1991;85:124-7.
 62. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. *Blood* 1997;90:3370-7.
 63. Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 Lesions in leukemic transformation. *N Engl J Med* 2011;364:488-90.
 64. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. *Proc Natl Acad Sci U S A* 2014;111(50):E5401-E5410.
 65. Beer PA, Delhommeau F, LeCouédic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. *Blood* 2010;115:2891-900.
 66. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood* 2015;125:1367-76.
 67. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. *Ann Intern Med* 1995;123:656-64.
 68. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. *Nature* 2015;518:552-5.
 69. Spivak JL. Polycythemia vera: myths, mechanisms, and management. *Blood* 2002;100:4272-90.
 70. Ellis JT, Peterson P, Geller SA, Rapaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. *Semin Hematol* 1986;23:144-55.
 71. Buhr T, Hebeda K, Kaloutsis V, Porwit A, Van der Walt J, Kreipe H. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. *Haematologica* 2012;97:360-5.
 72. Broséus J, Park JH, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. *Blood* 2014;124:3964-6.
 73. Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. *Leukemia* 2016;30:431-8.
 74. Lamy T, Devillers A, Bernard M, et al.

- Inapparent polycythemia vera: an unrecognized diagnosis. *Am J Med* 1997;102:14-20.
75. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. *Blood* 2008;112:231-9.
76. Cassinat B, Laguilleir C, Gardin C, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? *Leukemia* 2008;22:452-3.
77. Silver RT, Gjonj S. The hematocrit value in polycythemia vera: caveat utilitor. *Leuk Lymphoma* 2015;56:1540-1.
78. Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. *Blood Rev* 2016;30:453-9.
79. Wells RE Jr, Merrill EW. Influence of flow properties of blood upon viscosity-hematocrit relationships. *J Clin Invest* 1962;41:1591-8.
80. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythemia. *Lancet* 1978;2:1219-22.
81. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. *N Engl J Med* 2013;368:22-33.
82. Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. *Thrombosis* 2011;2011:874146.
83. Stein BL, Saraf S, Sobol U, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. *Leuk Lymphoma* 2013;54:1989-95.
84. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. *Am J Hematol* 2015;90:162-73.
85. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. *N Engl J Med* 2005;353:33-45.
86. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. *N Engl J Med* 1995;332:1132-6.
87. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. *Blood* 2012;119:1363-9.
88. Dameshek W. The case for phlebotomy in polycythemia vera. *Blood* 1968;32:488-91.
89. Rector WG Jr, Fortuin NJ, Conley CL. Non-hematologic effects of chronic iron deficiency: a study of patients with polycythemia vera treated solely with venesections. *Medicine (Baltimore)* 1982;61:382-9.
90. Alvarez-Larrán A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. *Blood* 2010;116:1205-10.
91. Sánchez-Luceros A, Meschengieser SS, Woods AI, et al. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution. *Haematologica* 2002;87:264-70.
92. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med* 2004;350:114-24.
93. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. *Semin Thromb Hemost* 2006;32:589-604.
94. Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. *Blood* 2013;121:1701-11.
95. Guglielmelli P, Rotunno G, Fanelli T, et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. *Blood Cancer J* 2015;5:e360.
96. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. *Blood* 2009;113:2895-901.
97. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol* 2011;29:392-7.
98. Hernández-Boluda JC, Pereira A, Gómez M, et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. *Haematologica* 2014;99(4):e55-e57.
99. Rotunno G, Pacilli A, Artusi V, et al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group. *Am J Hematol* 2016;91:681-6.
100. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med* 2012;366:799-807.
101. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. *N Engl J Med* 2015;372:426-35.
102. Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. *Blood* 2014;123:2157-60.
103. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. *Blood* 2015;126:790-7.
104. Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- α in a murine model of polycythemia vera. *Blood* 2013;121:3692-702.
105. Kiladjian JJ, Cassinat B, Chevrete S, et al. Pegylated interferon- α -2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. *Blood* 2008;112:3065-72.
106. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α -2a. *Blood* 2013;122:893-901.
107. Silver RT, Vandrisk K. Recombinant interferon alpha (rIFN α -2b) may retard progression of early primary myelofibrosis. *Leukemia* 2009;23:1366-9.
108. Them NC, Baginski K, Berg T, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon α -2b. *Am J Hematol* 2015;90:288-94.
109. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. *Expert Rev Hematol* 2013;6:49-58.
110. Kröger N. Current challenges in stem cell transplantation in myelofibrosis. *Curr Hematol Malig Rep* 2015;10:344-50.
111. Spivak J, Merchant A, Williams D, et al. A functional thrombopoietin receptor is required for full expression of phenotype in a JAK2 V617F transgenic mouse model of polycythemia vera. *Blood* 2012;120:427. abstract.
112. Wang X, Haylock D, Hu CS, et al. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. *Blood* 2016;127:3398-409.

Copyright © 2017 Massachusetts Medical Society.